Clinical Trial

AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis

Study acronym: LUMINA
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is a placebo-controlled Phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the antisense oligonucleotide (ASO) AMX0114 in adult participants with amyotrophic lateral sclerosis (ALS).
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2024-10-28; most recent amendment 2026-04-09.
Status change: Not Yet Recruiting → Recruiting 2025-02-05
Trial Details
NCT Number NCT06665165
Lead Sponsor Amylyx Pharmaceuticals Inc.
Conditions ALS
Enrollment 48 participants
Start Date 2025-04-07
Primary Completion 2027-02 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2026-04-14